Plasma microRNA signature is associated with risk stratification in prostate cancer patients.
Abeer Al-QatatiChristine AkrongInes StevicKlaus PantelJulius AweJeff SaranchukDarrel DrachenbergSabine MaiHeidi SchwarzenbachPublished in: International journal of cancer (2017)
The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-naïve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.
Keyphrases
- single cell
- prostate cancer
- radical prostatectomy
- end stage renal disease
- ejection fraction
- signaling pathway
- newly diagnosed
- chronic kidney disease
- cell proliferation
- prognostic factors
- long non coding rna
- computed tomography
- patient reported outcomes
- epithelial mesenchymal transition
- oxidative stress
- pi k akt
- mass spectrometry
- middle aged